Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …

Some cancers evade targeted therapies through a mechanism known as lineage plasticity,
whereby tumor cells acquire phenotypic characteristics of a cell lineage whose survival no …

This review summarizes key recent developments relevant to the pathologic diagnosis of
lung neuroendocrine neoplasms, including carcinoids, small cell lung carcinoma (SCLC) …

Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …

Metastasis is a major cause of morbidity and mortality in cancer patients. However, the
molecular and cellular mechanisms underlying the ability of cancer cells to metastasize …

Small cell lung carcinoma (SCLC) is a high-grade pulmonary neuroendocrine tumor. The
transcription factors ASCL1 and NEUROD1 play crucial roles in promoting malignant …

Purpose: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a highly aggressive
neoplasm, whose biologic relationship to small cell lung carcinoma (SCLC) versus non …

Loss of the tumor suppressors RB1 and TP53 and MYC amplification are frequent
oncogenic events in small cell lung cancer (SCLC). We show that Myc expression …